Adage Capital Partners’s Atrium Therapeutics RNA Stock Holding History
Bought
Maintained
Sold
Other funds holding RNA
Adage Capital Partners's RNA Position: Q3 2026 in Review
Adage Capital Partners held its Atrium Therapeutics (RNA) position steady in Q3 2026 at 100,000 shares worth $828K. The position accounts for ﹤0.01% of the portfolio, ranked #937.
Adage Capital Partners first reported a position in RNA in Q1 2026 and has held it in 3 quarters since. The position peaked at $2.45M in Q1 2026. 148 funds tracked by Wall St. Rank hold RNA as of Q3 2026.
- Adage Capital Partners held 100,000 shares of Atrium Therapeutics worth $828K as of Q3 2026.
- Adage Capital Partners left its Atrium Therapeutics share count unchanged in Q3 2026.
- Atrium Therapeutics made up ﹤0.01% of Adage Capital Partners's portfolio in Q3 2026, its #937 holding.
- Adage Capital Partners first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Adage Capital Partners's Atrium Therapeutics position peaked at $2.45M in Q1 2026.
- 148 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.
Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.